Non-squamous non-small cell lung cancer
Conditions
Interventions
Combination treatment with carboplatin (AUC = 5-6) + pemetrexed (500mg/m2) following with maintenance therapy with pemetrexed
Sponsors
Kurashiki Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically or cytologically diagnosed stage IIIB, stage IV or recurrence non-squamous non-small cell lung cancer 2. Without receiving cytotoxic agents chemotherapy 3. ECOG PS of 0-1 4. Life expectancy of more than 12 weekss 5. Adequate organ function Neutrophil cout of more than 1,500/mm3 Platelet cout of more than 100,000/mm3 Aspartate transaminase (AST), alanine transaminase(ALT): less than 100IU/L Total bilirubin: less than 1.5mg/dL Serum creatinine of less than 1.5mg/dL or creatinine clearance of less than 45mL/min
Exclusion criteria
Exclusion criteria: 1. Superior vena cava syndrome 2. History of severe hypersensitivity to drugs 3. Uncontrolled pleural effusion, peritoneal effusion, and cardiac effusion 4. Severe infectious disease or severe uncontrolled complication 5. Interstitial lung disease or pulmonary fibrosis 6. Active malignancy of other organ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Response rate, Rate of treatment completion | — |
Countries
Japan
Contacts
Public ContactToshihiko Kaneda
Kurashiki Central Hospital Department of respiratory medicine
Outcome results
None listed